Hypoplasminogenemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:722OMIM:217090L90.5
Who is this for?
Show terms as
1FDA treatments2Active trials8Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hypoplasminogenemia is a rare inherited condition where the body does not make enough of a protein called plasminogen. Plasminogen is made in the liver and plays a key role in breaking down blood clots and keeping mucous membranes — the moist linings of the body — healthy and clear. When plasminogen levels are too low, a thick, woody-textured tissue called ligneous (wood-like) tissue can build up on these moist surfaces. This condition is also known as plasminogen deficiency type I or ligneous disease. The most common and visible sign is ligneous conjunctivitis — a build-up of thick, yellowish-white membranes on the inner surface of the eyelids. This can cause pain, vision problems, and if left untreated, permanent eye damage. The same type of tissue can also grow in the gums, airways, ears, kidneys, and female reproductive tract. Symptoms can appear at any age but often start in childhood. Treatment focuses on replacing plasminogen to reduce or eliminate the abnormal tissue build-up. A plasminogen concentrate (Ryplazim) was approved by the FDA in 2021 and is the first specific treatment for this condition. Without treatment, the disease can significantly affect quality of life, especially vision and breathing. With proper care, many patients can manage their symptoms effectively.

Also known as:

Key symptoms:

Thick, woody membranes growing on the inner eyelids (ligneous conjunctivitis)Eye redness, irritation, and painBlurred or reduced visionThick tissue growths on the gums (ligneous gingivitis)Difficulty breathing if tissue grows in the airways or windpipeHearing problems if tissue grows in the ear canalsAbnormal tissue in the female reproductive tractKidney involvement in some casesRecurrent or slow-healing woundsSwollen or inflamed mucous membranes throughout the body

Clinical phenotype terms (16)— hover any for plain English
Decreased level of plasminogenHP:0040228Abnormality of the ovaryHP:0000137Abnormality of the middle earHP:0000370PeriodontitisHP:0000704Duodenal ulcerHP:0002588Abnormal fallopian tube morphologyHP:0011027CervicitisHP:0030160
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

2 events
May 2025Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis

Dorothy Bautista, MD — PHASE3

TrialENROLLING BY INVITATION
Dec 2018Study of Individuals Affected With Hypoplasminogenemia

Indiana Hemophilia &Thrombosis Center, Inc.

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Ryplazim

plasminogen, human-tvmh· ProMetic BioTherapeutics, Inc.Orphan Drug

Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia)

Clinical Trials

2 recruitingView all trials with filters →
Phase 31 trial
Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis
Phase 3
Enrolling by Invitation
PI: Dorothy V Bautista, MD (Memorial University of Newfoundland) · Sites: St. John's, Newfoundland and Labrador
Other1 trial
Study of Individuals Affected With Hypoplasminogenemia
Actively Recruiting
PI: Amy D Shapiro, MD (Indiana Hemophilia &Thrombosis Center, Inc.) · Sites: Birmingham, Alabama; Chicago, Illinois +28 more

Specialists

8 foundView all specialists →
AM
Amy Shapiro, MD
Specialist
PI on 1 active trial1 Hypoplasminogenemia publication
AM
Amy D Shapiro, MD
Specialist
PI on 2 active trials1 Hypoplasminogenemia publication
FP
Flora Peyvandi, MD, PhD
Specialist
PI on 3 active trials
CN
Charles Nakar
INDIANAPOLIS, IN
Specialist
2 Hypoplasminogenemia publications
RC
Roberto Crea
Specialist
2 Hypoplasminogenemia publications
JL
Jeremy Lorber
BEVERLY HILLS, CA
Specialist
PI on 1 active trial
KT
Karen Thibaudeau
GREENFIELD, NH
Specialist
4 Hypoplasminogenemia publications
DB
Dorothy V Bautista
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hypoplasminogenemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open HypoplasminogenemiaForum →

No community posts yet. Be the first to share your experience with Hypoplasminogenemia.

Start the conversation →

Latest news about Hypoplasminogenemia

No recent news articles for Hypoplasminogenemia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What are my plasminogen activity levels, and how low are they compared to normal?,Am I a candidate for Ryplazim infusion therapy, and how often would I need infusions?,Which organs should be checked for involvement, and how often should I be monitored?,Should my family members be tested for the PLG gene change?,What should I do if the eye membranes grow back between treatments?,Are there any clinical trials I could join for new treatments?,What emergency signs should prompt me to go to the hospital immediately?

Common questions about Hypoplasminogenemia

What is Hypoplasminogenemia?

Hypoplasminogenemia is a rare inherited condition where the body does not make enough of a protein called plasminogen. Plasminogen is made in the liver and plays a key role in breaking down blood clots and keeping mucous membranes — the moist linings of the body — healthy and clear. When plasminogen levels are too low, a thick, woody-textured tissue called ligneous (wood-like) tissue can build up on these moist surfaces. This condition is also known as plasminogen deficiency type I or ligneous disease. The most common and visible sign is ligneous conjunctivitis — a build-up of thick, yellowis

How is Hypoplasminogenemia inherited?

Hypoplasminogenemia follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Hypoplasminogenemia?

Yes — 2 recruiting clinical trials are currently listed for Hypoplasminogenemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hypoplasminogenemia?

8 specialists and care centers treating Hypoplasminogenemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Hypoplasminogenemia?

1 patient support program are currently tracked on UniteRare for Hypoplasminogenemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.